MedPath

YALE UNIVERSITY

YALE UNIVERSITY logo
🇺🇸United States
Ownership
Private
Established
1701-10-09
Employees
10K
Market Cap
-
Website
http://www.yale.edu
psychiatrictimes.com
·

The Tip of the Spear of A New Class of Antipsychotics

While FDA approval of Cobenfy for schizophrenia is significant, its role in treatment remains uncertain. Patients may resist switching from current antipsychotics despite Cobenfy's improved side effects. No direct comparisons exist yet between Cobenfy and other antipsychotics. John H. Krystal, MD, highlights upcoming treatments like emraclidine, emphasizing the value of multiple options for patients.
psychiatrictimes.com
·

The FDA Approval of Cobenfy: A Historic Moment in Schizophrenia

John H. Krystal, MD, discusses the FDA-approved schizophrenia treatment Cobenfy, the first drug with a novel mechanism in decades targeting M1 and M4 receptors without blocking D2. Cobenfy offers better tolerability and fewer adverse effects, potentially improving patient adherence and outcomes.
3dprint.com
·

Frontier Bio's Bioprinted Breakthrough: Lab-Grown Lung Tissue

Frontier Bio bioprinted human lung tissue, mimicking natural development with functional cilia, mucus production, and surfactant. This could transform drug testing and organ transplants, reducing reliance on animal models and donor organs.
markets.ft.com
·

Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President

Halda Therapeutics appoints Christian Schade as CEO, aiming to advance RIPTAC™ therapeutics for cancer treatment.
selectscience.net
·

Reducing lab errors in clinical chemistry with Joe El-Khoury

Prof. Joe El-Khoury, Director of Clinical Chemistry at Yale New Haven Health, focuses on kidney biomarkers like SDMA, mass spectrometry, and reducing lab errors. His research aims to improve CKD diagnostics and integrate advanced technologies into clinical practice, emphasizing the importance of global collaboration in laboratory science.
manilatimes.net
·

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for SCI-110

SciSparc's Phase IIb clinical trials for SCI-110, a potential therapy for Tourette Syndrome, have been approved by the FDA. The trial will be conducted at Yale, Hannover Medical School, and Tel Aviv Sourasky Medical Center, focusing on efficacy, safety, and tolerability of the drug in adult patients.
globenewswire.com
·

SciSparc Secures FDA Green Light to US Launch of its

SciSparc's FDA-approved Phase IIb clinical trials for SCI-110, targeting Tourette Syndrome, will proceed at Yale, Hannover Medical School, and Tel Aviv Sourasky Medical Center. The trial aims to assess SCI-110's efficacy, safety, and tolerability in adult patients.
biospace.com
·

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for ...

FDA approves SciSparc's SCI-110 for Phase IIb clinical trials in treating Tourette Syndrome, based on promising Phase IIa results showing significant tic reduction.
courant.com
·

Opinion: Goal is to reverse paralysis, if Washington doesn't get in way

Scientists have made breakthroughs in regrowing damaged neural connections, leading to promising clinical trials for spinal cord injury patients. However, recent tax law and patent regulation changes threaten to derail these treatments, potentially stifling medical innovation. A bipartisan bill aims to repeal harmful Section 174 changes, emphasizing the need for policies that support innovation.
© Copyright 2025. All Rights Reserved by MedPath